Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Specialty Chemicals grew 38% YoY for FY23
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Subscribe To Our Newsletter & Stay Updated
